Fast Market Research

Now Available: Iraq Pharmaceuticals & Healthcare Report Q3 2014

Fast Market Research recommends "Iraq Pharmaceuticals & Healthcare Report Q3 2014" from Business Monitor International, now available

 

Boston, MA -- (ReleaseWire) -- 07/24/2014 -- Thanks to the government's expansionary fiscal policy, spending on education, health and public services will increase . The Iraqi government has reportedly pledged to invest USD12bn into healthcare expansions in 2014, and the Ministry of Health recently awarded 18 health project contracts worth USD276mn . In addition, n ew restrictions aim to end the chaos in which materials have entered the country in previous years , targeting control over drug policy and ensuring the supply of medicines in adequate quantities and at reasonable prices. In general, the projected growth of Iraq's pharmaceutical market in 2014 and 2015 is linked to an oil-driven economic expansion, which is dependent on the government's ability to represent and appease the country's factions. Numerous factors, however, will continue to hamper market growth.

Headline Expenditure Projections

- Pharmaceuticals: IQD1,573bn (USD1.35bn) in 2013 to IQD1,772bn (USD1.52bn) in 2014; +12.6% in local currency and +12.8% in US dollar terms. Forecast unchanged from Q214.
- Healthcare: IQD9,701bn (USD8.33bn) in 2013 to IQD10,477bn (USD9.01bn) in 2014; +8.0% in local currency and +8.2% in US dollar terms. Forecast substantially lowered from Q214 due to macroeconomic conditions.

View Full Report Details and Table of Contents

Risk/Reward Rating

Iraq's Pharmaceutical Risk/Reward Rating (RRR) score for Q314 reflects the market's potential and its strong economic growth prospects. It performs better in terms of Rewards than Risks. In Q314 Iraq scores 41.9 out of 100, making it the 16th most attractive pharmaceutical market in the Middle East and African region. While its score has increased, the country's position is unchanged from Q214.

Key Trends And Developments

In May 2014, Zawya reported that Brazil exported pharmaceutical products worth USD15.5mn to Arab countries in 2013, citing the Arab-Brazilian Chamber of Commerce (ABCC). The top five importers were Egypt, Saudi Arabia, Sudan, Iraq and the United Arab Emirates. Brazil's...

The Iraq Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Iraq Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Iraqi pharmaceutical and healthcare industry.

Key Benefits

- Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Iraq to test other views - a key input for successful budgeting and strategic business planning in the Iraqi pharmaceutical and healthcare market.
- Target business opportunities and risks in the Iraqi pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Iraq.
- Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.

Coverage

BMI Industry View & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.

Market Summary

Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

BMI Industry Forecasts

Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Healthcare research reports at Fast Market Research

You may also be interested in these related reports:

- Egypt Pharmaceuticals & Healthcare Report Q3 2014
- Malaysia Pharmaceuticals & Healthcare Report Q3 2014
- Moldova Pharmaceuticals & Healthcare Report Q3 2014
- Peru Pharmaceuticals & Healthcare Report Q3 2014
- France Pharmaceuticals & Healthcare Report Q3 2014
- Turkey Pharmaceuticals & Healthcare Report Q3 2014
- Slovenia Pharmaceuticals & Healthcare Report Q3 2014
- United Kingdom Pharmaceuticals & Healthcare Report Q3 2014
- Lithuania Pharmaceuticals & Healthcare Report Q3 2014
- Jordan Pharmaceuticals & Healthcare Report Q3 2014